Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody

We report a patient with neuromyelitis optica (NMO) presenting anti-myelin-oligodendrocyte glycoprotein (MOG)-seropositive, in whom biomarkers of demyelination and astrocyte damage were measured during an acute attack. A 31-year-old man developed right optic neuritis followed by longitudinally exten...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2015-04, Vol.21 (5), p.656-659
Main Authors: Ikeda, Kensuke, Kiyota, Naoki, Kuroda, Hiroshi, Sato, Douglas Kazutoshi, Nishiyama, Shuhei, Takahashi, Toshiyuki, Misu, Tatsuro, Nakashima, Ichiro, Fujihara, Kazuo, Aoki, Masashi
Format: Article
Language:English
Subjects:
Adult
Antibodies, Blocking - therapeutic use
Astrocytes - pathology
Demyelinating Diseases - pathology
Glial Fibrillary Acidic Protein - metabolism
Humans
Magnetic Resonance Imaging
Male
Methylprednisolone - therapeutic use
Myelin-Oligodendrocyte Glycoprotein - antagonists & inhibitors
Myelin-Oligodendrocyte Glycoprotein - immunology
Myelitis, Transverse - complications
Neuromyelitis Optica - pathology
Neuromyelitis Optica - therapy
Neuroprotective Agents - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a patient with neuromyelitis optica (NMO) presenting anti-myelin-oligodendrocyte glycoprotein (MOG)-seropositive, in whom biomarkers of demyelination and astrocyte damage were measured during an acute attack. A 31-year-old man developed right optic neuritis followed by longitudinally extensive transverse myelitis, fulfilling the criteria for definite NMO. He was anti-MOG-seropositive and anti-aquaporin-4 seronegative. The myelin basic protein level was markedly elevated whereas glial fibrillary acidic protein was not detectable in cerebrospinal fluid during an acute attack. His symptoms quickly improved after high-dose methylprednisolone therapy. This case suggests that NMO patients with anti-MOG may have severe demyelination in the absence of astrocyte injury.
ISSN:1352-4585
1477-0970
DOI:10.1177/1352458514551455